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Abstract
In the mid-90s, hepatitis B virus (HBV)-directed immune responses
were for the first time investigated in detail and revealed
suboptimal T-cell responses in chronic HBV patients. Based on
these studies, therapeutic vaccination exploiting the antigen
presentation capacity of dendritic cells to prime and/or boost HBV-
specific T-cell responses was considered highly promising. Now,
25 years later, it has not yet delivered this promise. In this review,
we summarise what has been clinically tested in terms of antigen
targets and vaccine forms, how the immunological and
therapeutic effects of these vaccines were assessed and what
major clinical and immunological findings were reported. We
combine the lessons learned from these trials with the most recent
insights on HBV antigen presentation, T-cell responses, vaccine
composition, antiviral and immune-modulatory drugs and disease
biomarkers to derive novel opportunities for the next generation
of therapeutic vaccines designed to cure chronic HBV either alone
or in combination therapy.
Keywords: antigen presentation, chronic HBV infection, HBV,
hepatitis B virus, HLA, therapeutic vaccination
INTRODUCTION
The hepatitis B virus (HBV) is a non-cytopathic
virus that specifically infects hepatocytes
(reviewed by Lampertico et al.1 and Tu et al.2).
The circular double-stranded DNA composed viral
genome is very small (3.2 kbp) and contains 4
overlapping open reading frames (ORF) encoding
three forms of HBV surface antigen (HBsAg;
small, medium and large), the viral capsid-
forming core (HBcAg) and its secreted form the e
antigen (HBeAg), the viral DNA Polymerase (Pol)
and lastly the non-structural X protein that
regulates viral protein transcription. These ORFs
are translated directly from covalently closed
circular DNA (cccDNA) residing as a mini-
chromosome in the nucleus of infected cells.
Presumably to divert the immune system,
infected hepatocytes not only secrete infectious
viral particles, but also large amounts of HBeAg
and HBsAg. The latter is secreted as empty,
membrane enclosed, subviral particles. Soon after
infection, the virus also integrates into the host
genome, which contributes to hepatocellular
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carcinoma (HCC) development and viral
persistence (reviewed by Tu et al.2). However,
integration is not required for replication, which
happens via cccDNA. Integration occurs from
linearised viral DNA in which both Pol and
HBcAg lose connection to their promotor,
abrogating protein production. HBsAg and X,
however, are likely readily produced from
integrated DNA.
Although most adults can successfully clear an
acute HBV infection, around 5% of adults and
most perinatal infected infants develop a chronic
HBV infection (cHBV). These patients are at risk of
developing life threatening liver disease including
HCC.1 Although direct oncogenic effects have
been attributed to the X protein, cancer risk is
also imposed by tissue damage resulting from the
ongoing battle between HBV and the immune
system. Initially, most patients experience a non-
inflammatory phase with high viral titres (HBeAg-
positive chronic infection (EPCI; Table 1), followed
by an inflammatory phase (HBeAg-positive chronic
hepatitis (EPCH)) with immune-mediated liver
damage (i.e. ALT rise), fluctuating viral titres and
ongoing expression of HBeAg. At some point,
HBeAg expression may cease either or not in the
presence of anti-HBeAg antibodies and patients
may enter a phase of partial immune control
characterised by low viral titres (HBeAg-negative
chronic infection (ENCI)) in which most serum
HBsAg derives from integrated DNA.3 Loss of
HBeAg represents partial viral control, associates
with HBV DNA decline and may precede HBsAg
loss. Viral replication, however, may still return
and lead to HBeAg-negative chronic hepatitis
(ENCH). A fifth but rare phase of HBV infection is
characterised by absence of HBsAg in the serum
with or without the presence of anti-HBcAg and
anti-HBsAg immunoglobulins. Patients in this
phase have normal ALT levels and detectable HBV
DNA in serum and liver tissue.1 Currently, the only
effective drugs are nucleos(t)ide analogs (NAs)
that suppress viral replication, but offer no
immune control and leave protein production
intact and hence are recommended to be taken
lifelong.1,4 High costs limit NA availability and
HCC risk is decreased, but not abrogated.
Therefore, short-term treatment that can establish
full viral immune control, also called ‘a functional
cure’ is highly demanded.4 A functional cure is
reached when, in the absence of therapy, viral
replication is maintained below detection limit
and accompanied by the loss of serum HBsAg
either or not in the presence of anti-HBsAg
immunoglobulins.
Studies in chimpanzees have demonstrated that
T cells represent a major factor associated with
HBV immune control and clearance.5,6
Concordantly, T-cell responses are far more
abundant and of higher quality in acute clearing
patients as compared to cHBV.7–9 Hence, finding
ways to activate, boost or introduce HBV-directed
T-cell responses has been a focus of research for
two decades. Ways to restore/obtain T-cell
responses include immune checkpoint blockade
(ICB), therapeutic vaccination (TV) and adoptive T-
cell therapy.10 ICB will mostly act on existing
responses while TV may also activate de novo
responses. Here we will focus in detail on the
clinical and immunological achievements of TV to
harness T-cell responses relying on antigen
presentation by dendritic cells (DCs) and will
explore remaining opportunities for TV. We will
reflect on the implications of HBV antigen
expression and HLA presentation as well as HBV
disease stage. Furthermore, we will discuss recent
developments with respect to immune and virus
monitoring, vaccine composition and delivery and
Table 1. Overview of previous and new nomenclature on the different phases of HBV infection1
Previous nomenclature Immune Tolerance Immune Active/Clearance Inactive carrier Immune Escape/Reactivation
HBV DNA High High Low High
HBsAg High High/intermediate Low Intermediate
HBeAg Positive Positive Negative Negative
Liver Function Tests (LFTs) Normal Abnormal Normal Abnormal
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will touch upon combination therapies that could
facilitate TV to cure cHBV.
PRIMING AND FUNCTION OF T CELLS
IN CHRONIC HBV INFECTION
Central to successful T-cell priming and effector
function is the process of antigen presentation by
DCs and infected hepatocytes. To discuss the
opportunities for TV we will first provide a brief
outline of the ‘state of the art’ on HBV antigen
processing and presentation by DCs, and the
quality of HBV-cognate T cells in cHBV.
Dendritic cells
Dendritic cells recognise and take up pathogens
or diseased, malignant or dying cells using a
repertoire of pattern recognition receptors.11
Ingested material is processed by their
intracellular machinery dedicated to antigen
presentation on both HLA II (HLA-DR/DP/DQ) and
HLA I (HLA-A/B/C) to prime (i.e. first time activate)
CD4+ and CD8+ T cells respectively, supported by
DC expressed co-stimulatory receptors and
cytokines. DCs excel in presentation of exogenous
material on HLA I, which is called cross-
presentation. Because HBV does not infect DCs,
the priming of HBV-specific CD8+ T cells by DCs
during HBV infection relies on DC cross-
presentation.12 Their unique T-cell priming and
stimulation capacity renders DCs of extreme
importance for cHBV treatment as HBV-clearing T-
cell responses could be initiated, boosted or
qualitatively improved by ensuring that
adequately matured DCs present the right HBV
antigens.13 DCs can be used directly as a cellular
vaccine, be targeted in situ/vivo by proteins,
peptides, or particles designed to bind DC-specific
surface receptors or be targeted more passively by
exploiting the unique cross-presentation capacity
of DCs.14,15 The latter, for example, would be the
case for vaccines based on whole proteins or
synthetic long peptides (SLP).
Important for TV design is that DCs in cHBV
need to be sufficiently operational, which is a
highly debated topic. Many studies have described
impairment of DCs to phenotypically mature or
secrete cytokines directly after isolation from
patient blood or livers, while others report DCs to
be fully functional.13,16–19 Of note, many forms of
TV are administered to the skin (intradermally or
subcutaneously) or muscle and thus rely on
intradermal and/or lymph node (LN) DC2 & DC1
for optimal CD4+ and CD8+ T-cell priming
respectively.20,21 To our knowledge, functionality
of intradermal or LN DC has not been studied in
cHBV.
Thus far, both HBsAg and HBeAg have been
demonstrated to suppress DCs in vitro (reviewed
by Woltman et al.22). However, in vivo immune
exhaustion, chronic inflammation, nutrient
depletion, or cell stress is often seen in cHBV and
could also affect DCs and confound results.
Furthermore, inconsistencies between studies may
have related to the source material (i.e. peripheral
blood or liver), cHBV disease stage and/or
treatment regime.
Despite the observations that T-cell responses in
general (i.e. also non-HBV-specific) may be
dysfunctional in cHBV, there is currently no strong
evidence that cHBV patients are impaired in their
general ability to respond to pathogens or
common vaccines, indicating that DCs are at least
not greatly dysfunctional.23–25 Nonetheless, DCs
may be of best quality in individuals with low
viral load and liver inflammation (i.e. low ALT
levels).18,22,26
T cells
For TV design, it is pivotal to consider the quality
of the T-cell population. The state of HBV-cognate
T cells will be affected by the level and context of
antigen presentation during priming of T cells,
which is likely different for each viral antigen.
Because Pol and X are expressed at a much lower
level than HBsAg and HBcAg, that constitute the
largest amount of protein in viral particles, HLA
presentation from Pol and X is also likely to be
lower.27,28 However, few quantitative data on
HBV protein expression are available.
Furthermore, Pol and X are not (efficiently)
secreted and therefore might reach DCs to a lesser
extent. For these antigens hepatocytes are likely
responsible for most of the T-cell priming.
Hepatocytes, however, lack proper co-stimulatory
signals to adequately prime CD8+ T cells and are
also less able to activate CD4+ T cells.29
Hepatocyte primed dysfunctional CD8+ T cells,
however, can be rescued by IL-2.30 Because of
these limitations, effective DC cross-presentation
of Pol and X peptides and subsequent priming of
cognate T cells may be restricted to highest
affinity peptides only. In contrast, average affinity
peptides derived from HBsAg or HBcAg/HBeAg
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could already do the job.31 Conversely, secreted/
virus-contained HBeAg/HBcAg and HBsAg readily
reach DCs and consequently may more
abundantly prime T cells. HBsAg- and HBeAg/
HBcAg-cognate T cells for this very same reason
could also be more prone to antigen overload-
driven deletion or exhaustion.25,32–34 T-cell
deletion is most severe for HBsAg-directed T cells
and specifically for this antigen relates with age/
exposure time rather than serum HBsAg levels.35 T
cells recognising HBcAg are likely also affected by
antigen overload, but partially restore after
clearance of HBeAg, which is largely identical in
amino acid sequence.10,23
An effectively primed, high affinity T cell
requires only few HLA-peptide complexes to exert
effector function.36 An outstanding question is
how the hepatocyte HBV antigen expression levels
that are needed to sustain the infection, relate to
levels needed by CD8+ T cells to detect the
infected cell. For endogenous HLA I presentation,
protein abundance, intracellular location and
turnover are important.37 Because HBsAg and
HBcAg are crucial for viral particle formation,
many more molecules of these proteins may be
required for viral persistence than copies of Pol or
X, which will also reflect on the presentation of
these antigens on infected hepatocytes.27,38 Yet,
also HBcAg and HBsAg each have their own
antigen presentation rules. Khakpoor et al.39
recently found that in ENCH patients presentation
of a HBsAg epitope was spatially separated from a
HBcAg epitope. It was postulated that high HBsAg
presentation on cells from integrated DNA may
serve as a decoy for T-cell responses to spare bona
fide infected hepatocytes (with possibly lower
HBsAg presentation levels).
In line with differences in antigen presentation
levels and cellular context during priming (e.g. by
DCs or hepatocytes), three recent studies reported
qualitatively different responses against HBcAg
and Pol.33,34,40 HBcAg-directed T cells were found
less dysfunctional (i.e. with better ex vivo
proliferation potential and cytokine secretion)
and more of an effector memory (Tem)
phenotype than those recognising Pol, which
were mostly terminally differentiated effectors
(Temra). This was, however, not associated with
higher exhaustion marker expression on Pol-
cognate T cells. Exhaustion markers were found
on all HBV-recognising T cells regardless of
protein specificity. Pol-specific T cells rather
expressed more KLRG1. Intriguingly, part of the
Pol-specific T cells displayed a na€ıve
phenotype.33,34,40 Also in acute HBV infection PD-
1 expression was lower on Pol-specific cells
compared to HBcAg- and HBsAg-specific T cells
and Pol-specific T cells were less functional
ex vivo.34 Furthermore, also in acute patients
HBcAg-specific T cells were more of the Tem
phenotype and Pol-cognate T cells predominantly
Temra. Presence of this phenotypic difference in
both chronic and acute patients supports a
mechanism independent of chronic disease which
may include inherent differential antigen
presentation and T-cell priming (above; 34).
Interestingly, for memory responses and
specifically for generation of Tem over Temra
CD4+ T cell help is required.41 In this regard
evidence for an important role of CD4+ T cells in
clearing cHBV is accumulating.6,42–44 Besides
helping CD8+ T cells, CD4+ T cells support B cell
responses and might even harbour effector
function themselves.45 CD4 effector action could
occur indirectly via HLA class II presentation on
nearby cytotoxic macrophages or even directly
since hepatocytes under certain circumstances also
express HLA class II.46–48 CD4 effector functions
may thus potentially contribute to clear cHBV.
Wrongly skewed CD4+ T cells, however, can also
induce liver damage.43
PAST CLINICAL STUDIES ON HBV
THERAPEUTIC VACCINATION
In light of their ability to drive T-cell responses
against each of the viral proteins and of their
clinical effect we have evaluated past clinical TV
studies. TVs so far have been either based on
HBV-derived peptides or proteins (Table 2),
genetically encoding (parts of) HBV antigens
(Table 3) or based on in vitro loaded monocyte-
derived DCs (moDCs; Table 4). Many of these past
trials mainly focused on viral persistence and did
not very elaborately monitor immune responses,
either only assessing antibody production and/or
using T-cell assays not discriminative for CD4+ or
CD8+ T-cell responses (e.g. IFNc ELISpot). Initial
TVs targeted only HBsAg. Over the years HBsAg
remained a popular target. However, ex vivo
(above) and in vivo (Tables 2–4) evidence suggests
targeting HBsAg alone may not be very effective.
Treatment of cHBV patients with peptide-based
GenVacB or Sci-B-Vac (Table 2), protein-based YIC
(Table 2) or DNA vaccines pCMV-S2.S and ED-DNA
(Table 3) targeting HBsAg only, induced a
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decrease or even disappearance of HBV DNA, but
always transiently.49–54 HBsAg TV did induce
HBsAg-directed antibody responses in several
cases, but ultimately without lasting effect on
HBsAg levels.50,55 Those HBsAg-based TV trials
that monitored T cells found that T-cell responses
to HBsAg were very low.52,56 It is notable that the
majority of peptide- and protein-based vaccines
targeting HBsAg used alum as adjuvant. While
alum supports production of protective
antibodies, it does not facilitate cytotoxic T-cell
responses.57 Other TVs, targeting HBsAg alone,
however, were based on other vaccine platforms
and/or were supported by different adjuvants,
including AS02B, an oil in water, saponin and
TLR4 ligand-based adjuvant and DNA-based TVs
co-encoding CpG (pCMV.S2.S) or IL-12 and IFN-ɣ
(ED-DNA).52–54 Each of these vaccines induced
transient T-cell responses except for ED-DNA,
which only induced T cells in patients displaying
also a virological response to NA treatment
started prior to ED-DNA administration.54 Further
of interest is that increasing the dosing frequency
(of pCMV-S2.S and YIC) did not necessarily
augment immune responses or clinical effect,
which for YIC was attributed to vaccine induced
immune exhaustion.52,58
Considering the remaining T-cell population in
cHBV, targeting HBcAg, Pol or preferably even a
collection of (partial) HBV antigens likely holds
more promise than targeting HBsAg alone. Only
one study targeted HBcAg alone using the
immune dominant HLA-A2 restricted HBcAg18–27
epitope attached to a Tetanus Toxid (TT) helper
epitope (Theradigm-HBV).59 Although without
clinical effect, the Theradigm-HBV study
highlights that CD4+ T-cell responses are
important for the induction of primary, but not
secondary CD8+ T-cell responses and for CD8+ T-
cell longevity. Furthermore, TT-directed CD4+ T
cells and also PHA stimulated T cells from cHBV
patients, but not HCV patients, were skewed
towards IL-15-producing Th2 ex vivo. CD4+ T cells
from healthy individuals, in contrast, produced
the Th1 cytokines IL-12 and IFNc.42 These findings
point to a more general Th skewing defect in
cHBV patients. A mechanism could involve HBeAg
present in the serum of Theradigm-HBV treated
patients that can drive unfavorable Th0/Th2
skewing.60
Besides single antigens, several different
combinations of 2 to all HBV proteins have been
targeted by TV either as whole proteins (i.e. alum
supported NASVAC), DC ex vivo loaded with
whole proteins or HLA-peptides, yeast cells
expressing whole protein (GS-4774) or DNA (HB-
100, HB110; both co-encoding IL-12) or adenovirus
encoding antigens (TG1050; Tables 2–4). Although
also none of the multi-antigen TV thus far yielded
objective clinical effects, (transient) virological
and/or T-cell responses were induced by several.
Peptide-pulsed autologous DCs yielded a
promising tendency towards increased HBeAg
seroconversion especially when added to NA
therapy. Unfortunately, no T-cell responses were
assessed.61 Responses against DNA vaccine HB-100
(together with NA therapy) were mostly CD4+ and
highest in patients with decreasing viral load.
Induced CD4+ HBV-specific central memory T cells
persisted up to 40 weeks after the last injection.62
Of interest is that the HBeAg status related to the
in vivo T-cell response to HBcAg, in line with prior
in vitro work.23 Also autologous DCs loaded with
HBcAg and HBsAg performed better in HBeAg-
negative compared to positive patients.26
Adenovirus-based TG1050 was tested primarily in
HBeAg-negative patients (only 3 out of
48 = 6.25% was HBeAg-positive) and here
strongest responses were detected against HBcAg
by IFNc ELISpot.63 Also for yeast-based GS-4774,
IFNc ELISpot for HBcAg was significantly more
productive in the HBeAg-negative patients (63.3%
in HBeAg neg versus 35% in HBeAg pos).64 GS-
4774 (in combination with NAs) significantly
induced T cells cognate for vaccine contained
HBcAg (directly ex vivo) and HBsAg (after in vitro
culture only) but not X. Despite effective CD8+ T-
cell induction, GS-4774 started together with NAs
in treatment naive patients did not yield any
reduction in HBsAg over NAs alone. The lack of
clinical effect may be explained by failure of GS-
4774 to induce CD4+ T-cell responses. Important to
note, however, is that GS-4774 was based on HBV
genotype D and most treated patients were Asian
(likely infected with genotypes B and C) and 60%
were HBeAg negative. T-cell monitoring, however,
was restricted to a small set of patients infected
with genotype D which were all HBeAg negative.
In the immune monitoring subgroup, both
ethnicity and HBeAg status likely positively
affected T-cell response induction. Thus GS-4774
may not to have been optimally matched to the
patient population and the reported CD8+ T-cell
responses were not entirely representative for the
cohort in which the clinical effect was assessed.
Though, an important observation from the GS-
2021 | Vol. 10 | e1232
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4774/Tenofovir study was that Pol-specific
cytokine-producing T cells were triggered, while
polymerase was not included in the vaccine.65 An
explanation provided was a yeast adjuvant effect
on Pol-presenting DCs. In addition, it is possible
that epitope spreading after cytolysis of infected
hepatocytes, releasing Pol to DCs could have
contributed.
Taken together, a wide variety of TV strategies
have been developed and tested in clinical trials
over the years with limited clinical success. Yet,
the lessons learned from past clinical trials
together with recent insight with respect to T-cell
responses in cHBV now set the stage for the
design of new and improved TV strategies.
DESIGNING THE NEXT GENERATION OF
VACCINES
So far, despite induction of antibodies or T cells
by some, no form of TV convincingly induced
lasting viral control and HBsAg seroconversion in
a significant number of patients. From other
chronic infections and cancer, we can derive that
immune suppressive mechanisms likely contribute
highly to the lacking clinical effect and that
combination with drugs lifting these mechanisms
could be key also in cHBV.66,67 However, such
drugs will depend on the size and quality of the
immune response at the time of administration.
Therefore, to offer combination therapies the best
starting point it is still paramount to carefully
select the target antigen(s), vaccine platform,
adjuvants, route of administration and patient
population for TV. Furthermore, to allocate the
best opportunities for combination (immune)
therapy, both immunological and viral response
monitoring alongside future TV clinical trials
needs great detail and careful design.
Vaccine target antigens
To limit competition between vaccine antigens
their selection needs to be well-considered. The
off-target Pol response seen upon GS-4774
vaccination indicates that not all HBV proteins
need to be targeted to get a broad polyclonal
response. One or a few well-chosen hits could
kick-start a self-propagating response. Pinpointing
exactly which T-cell responses can trigger such a
response to drive viral clearance has proven
difficult. Recently, Bertoletti and co-workers
demonstrated that prior to stopping NA therapy,
non-flaring patients displayed higher numbers of
Table 4. Dendritic cell vaccines
DCs type & handling
Groups, Route &







HBV DNA > 105 mL−1
n = 19
No HBsAg loss or anti-HBsAg, ↓ HBV
DNA: 11, HBeAg loss: 10/11, Anti-
HBeAg: 5/11, DCs + LAM; HBV









antiviral therapy > 6M
n = 380
HBeAg+: HBeAg loss: 55/185
Anti-HBeAg: 40/185 ↓ DNA > 2 log
10: 71/160 HBV DNA neg: 5/160
HBeAg; HBsAg loss: 20/195, Anti-







TNFa, IL1b & PGE2
matured





with HBV DNA > 104
copies mL−1, no antiviral
therapy > 1 y
n = 80
No HBsAg loss or anti-HBsAg, HBV
DNA neg: 19/20 of DC + ETV vs
13/20 ETV only
HBeAg loss: 11/20 DC + ETV vs
7/20 ETV only, Anti-HBeAg: 8/20










Therapeutic potential not measured.
No ↓ HBV DNA, Anti-HBs: 2 of
which 1 transient
No data 131
>, followed by; ↓, decrease; Ag, antigen; ETV, entecavir; FU, follow-up; ID, intradermal; IV, intravenous; LAM, lamivudine; m, month; NA,
nucleot(s)ide analog; neg, negative; SC, subcutaneous; vs, versus; w, week.
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HBcAg- and/or Pol-specific T cells.68 Furthermore,
Newell and colleagues identified HBcAg-cognate T
cells to associate with viral control, both between
cHBV patient groups (i.e. with more, fitter and
public TCR carrying T cells in resolver and ENCI
over EPCH patients), and longitudinally towards
HBeAg clearance and anti-HBeAg seroconversion
(i.e. a higher quality of HBcAg-specific T cells at
NA start40). Lastly, Deng et al.43 found that during
a flare IFNɣ-producing CD4+ T cells specific for
HBcAg and HBsAg associated with HBeAg and
HBsAg clearance respectively. Importantly, TNFa-
producing HBcAg-specific CD4+ T cells rather
associated with liver damage. While these studies
indicate that boosting/triggering CD8+ T-cell
responses against HBcAg and Pol and CD4
responses against HBcAg and HBsAg may be most
interesting, evidence is still circumstantial. To
rationally design TV we believe it is still pivotal to
gain mechanistic insight into why specific
responses are preferred over others. Knowing for
example which viral HLA I epitopes are presented
even at low viral replication would greatly
contribute. Furthermore, despite recent efforts
into this direction, still more detailed data are
required on (the parts of) viral antigens for which
a salvageable CD8+ T-cell population remains in
most cHBV patients. For now, HBcAg and Pol may
have the best cards. If, however, HLA I
presentation of Pol by infected hepatocytes is
truly very inefficient, one could argue that Pol can
still support viral replication at ‘sub-HLA’
expression levels. Yet, Pol-directed immune
responses could still suppress viral replication to a
manageable viral load and give opportunity to
responses of other specificities to clear the
infection.68 Of note, HBsAg and X remain of
special interest as targets in HBV-derived HCC as
these proteins are expressed from integrated DNA
also in tumor cells.69
Regardless of the chosen target antigen(s), it is
now clear that to obtain effective and long-
lasting CD8+ T-cell responses, CD4+ T-cell help is
required and thus both CD4 and CD8 epitopes
should be included in a vaccine.21 Because the
same DC1 in the lymph node likely needs to
present both CD4 and CD8 epitopes, and because
antigen-specific CD4+ T-cell help is also important
for recruitment to and proliferation of CD8+ T
cells at the target tissue, physical linkage of these
epitopes is desired.21,70,71 Finally, genetic
variability between HBV genotypes demands
either making genotype specific or personalised
vaccines, or rather a focus on conserved parts of
viral antigens.72
Vaccination platform
To pinpoint which platforms have highest T-cell
activating potency, we can learn from other
disease settings targeting viral- or neoantigens.73–77
In chronic human papilloma virus (cHPV)-infected
patients with pre-malignant lesions, both SLPs
and DNA vaccines could clear viral disease and
lesions in a large proportion of patients.73–75
Importantly, the strength of the SLP-induced
responses directly correlated with clinical effect.78
Thus, both SLPs and DNA/RNA vaccination have
proven efficacy to induce a virus clearing cellular
response and for this reason are of special
interest. DNA or RNA vaccines can support HLA I
presentation by DCs via co-translational peptide
loading (rather than cross-presentation)
potentially benefiting CD8+ T-cell responses
(reviewed by Pardi et al.79). Both also readily
induce CD4+ T-cell responses.62,76 Further
considerations for vaccine platform choice are
that whole proteins are ineffectively cross-
presented and thus not very potent to induce
CD8+ T-cell responses.80 Shorter protein
fragments or SLPs are better cross-presented and
may harness responses also against (potentially
less exhausted) subdominant CD8 epitopes.81
Using HLA-restricted exact CD8+ T-cell epitopes
for TV is likely not preferred as it can lead to
tolerance as a result of presentation by non-
professional APCs or T cells.20 CD4+ T-cell
presentation and processing of HLA II epitopes is
more promiscuous and both whole proteins and
shorter fragments could be effective.21
Furthermore, for protein-based TV, particulation
may facilitate CD8+ T-cell induction and Th1
skewing.82 Currently, SLP-based vaccines for cHBV
are in (pre-) clinical development by us and
others.13,72,83,84 In addition, several other protein-
based forms of antigen delivery are currently
assessed in pre-clinical studies: modified cell-
permeable HBV capsids are tested to deliver HBV
antigens to the DCs cytoplasm to favor HLA I
presentation.85,86 Furthermore, a chimeric fusion
protein consisting of the Fc fragment of a
murine antibody and HBV antigens is tested
targeting HBV antigens to DCs via Fcɣ and
mannose receptors.87
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Possibly, one platform alone may not do the
job. As such heterologous prime-boost vaccine
regimens have proven to be an effective strategy
to induce both humoral and cellular immune
responses.88–90 A HBsAg-containing DNA vaccine
prime combined with a modified vaccinia virus
Ankara (MVA) boost has already been tested in
the clinic (TherVacB91). Improvements of this
strategy by targeting HBcAg instead HBsAg and
addition of a TLR-ligand (i.e. CpG) are currently in
the pre-clinical phase as are other combinations
of prime and boost formulations targeting
multiple HBV antigens such as chimpanzee
adenoviral and MVA vectors or attenuated
vesiculostomatitis virus-based platforms.90,92,93
Adjuvants
Adjuvants are in many cases crucial to prevent
presentation of antigens in a tolerogenic context.
It is important, however, to tailor the adjuvant to
the mechanism of action and desired outcome of
the TV platform. As indicated, alum is not the
best choice when a cellular response is aimed for.
Protein- and peptide-based TV may be best
supported by an adjuvant triggering DC
maturation during antigen uptake and thus
linking the two can be favorable.83,94 The cross-
presentation supporting adjuvant ISCOMATRIX is
being tested as adjuvant for an HBsAg/HBcAg
containing vaccine (DV601) and a preliminary
report indicated induction of cellular responses.95
Alongside SLP vaccines in (pre-) clinical
development, TLR9 ligand IC31 (i.e. for HepTcell)
and TLR2 and TLR3 ligands are used to improve
vaccine effect.83,84,96 While TLR2 and TLR3 can be
readily found on the myeloid DCs that are likely
needed for TV effect, this is different for TLR9
that in humans is predominantly found on pDCs
and B cells.14 TLR9 ligands, however, could still
support cross-presentation via the secretion of
Type I interferons.
RNA and DNA vaccine platforms require a
completely different adjuvant strategy as the
target antigen first needs transcription and/or
translation. Nucleic acid-based platforms
potentially contain intrinsic adjuvant capacity
triggering nucleic acid recognising PRR. This may
also hamper their effect because an IFN induced
translational shutdown can impair vaccine
encoded antigen expression. Most recent RNA-
based vaccines have been optimised to prevent
this. Genetic vaccines benefit most from
co-encoded cytokines (such as IL-12 for HB100 and
HB110), co-stimulatory agonists or constitutively
signalling receptors.79
Route of administration
Most cHBV vaccines thus far relied on
intramuscular administration, some on
subcutaneous injection and one on intranasal
delivery (Tables 2–4). While intramuscular and
subcutaneous routes are practical, well-tolerated
and equally adequate to trigger IgG1 antibody
responses, they do not optimally trigger Th1
responses.97 More effective may be intranodal or
intradermal vaccination that either directly bring
the antigen to the site of action or use the vast
network of skin resident migratory DCs for
transport to the lymph nodes respectively.98,99
Intradermal vaccination and even more so
intranodal vaccination are effective at lower dose
as compared to intramuscular or subcutaneous
routes.98,100 Intranodal delivery was recently used
in a highly promising RNA vaccination strategy
applied to melanoma patients.76 A drawback of
these routes of administration is that they require
more training.
Patient population
cHBV disease stage likely greatly affects treatment
outcome. Several studies show that in HBeAg-
negative patients, HBcAg-cognate T-cell activation
is more effective and immune fitness greater as
compared to HBeAg-positive patients, which is
associated with higher mutation driving immune
pressure.23,62,64,101 Mechanism could involve less
exhaustion of HBcAg-specific T cells due to the
absence of HBeAg, and relief from unfavorable Th
skewing and/or induction of myeloid suppressor
cells by HBeAg.60,102 Furthermore, T-cell responses
are better in patients with low viral load/ALT and
DCs are more fit.18,22,25,26,32,103 Low viral load may
arise naturally or can be achieved by NA therapy.
NA therapy, however, only transiently improves T
cells’ responses, possibly reflecting initial rescue
from antigen overstimulation and subsequent
memory retraction of T cells.104
While at first patients with high viral load and
ALT were mostly treated with TV, later co-
administration with NAs became more common.
For safety reasons and because T cells may be
most salvageable, nowadays many trials start TV
treatment after a longer period of NA treatment
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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and/or restrict patient inclusion to those with low/
absent viral load. Important to consider, however,
is that especially ENCI patients on NA therapy may
have little viral activity remaining and serum
HBsAg mostly derives from integrated DNA.3
Therefore, a beneficial effect of TV may not
become immediately apparent and may require
NA discontinuation to revive virus replication and
antigen presentation. This to further boost the
induced immune response and allow it to clear
the virus.105 Although NA stop was not successful
following HBsAg-based vaccines (i.e. NASVAC and
pCMV.S2.S), NA stop has not yet been attempted
following vaccines targeting HBcAg or Pol and/or
vaccines that were successful in triggering cellular
immune responses (above). The latter is important
because in particular HBcAg- and/or Pol-directed
T-cell responses could limit flares upon NA
discontinuation.68 Such T cells were deemed
necessary to be present already prior to the flare,
suggesting that TV prior to NA discontinuation
could give HBcAg- and Pol-specific T cells a head
start on a possible revival of HBV replication.
Although preventing a flare is surely a safer
option on the short term, limited ‘flaring’ may
accompany a beneficial HBV-directed immune
responses and ultimately HBsAg seroconversion
giving a long-term benefit.4 NA re-treatment
rules, however, should be carefully designed
when considering stopping NAs.
Despite high DNA levels, young patients
without liver damage could still represent an
interesting target population as they are
endowed with a more sizable and variable HBV-
directed T-cell population and may thus respond
better to TV.35,106 Yet also (or even in particular)
for this population suppression of viral replication
with prior NA therapy will likely be needed to
fully harness T cells and to warrant safety. A
requirement for low viral load could complicate
patient inclusion as these patients most often lack
clinical symptoms and are not by default treated
with NA therapy.1
Outcome measures
To exploit TV for cHBV both viral and
immunological responses need close and detailed
monitoring. For past trials, monitoring was often
restricted to measuring HBsAg levels and HBsAg-
directed antibodies (Tables 2–4). We now know
these parameters do not optimally reflect vaccine
efficacy as both the clearing of HBsAg and the
development of HBsAg-directed antibodies are
relatively ‘late’ events on the road to viral
clearance. Monitoring should perhaps focus more
on obtaining a broad and qualitative view of
vaccine immunogenicity and on finding more
subtle signs of improved viral immune control.
This is needed to reveal where a vaccine has an
effect and to find out where further improvement
of design and/or combination (immune) therapy
could be applied to tip the balance.
From clinical successes in cHPV and cancer we
know that the strength of the induced immune
response is very important and that ultimately
success may depend on counteracting T-cell
dysfunction.66,76–78,107 Therefore, a broad and
antigen-specific overview of induced T-cell
responses is needed and as much detail as possible
on the size and quality (e.g. skewing, level of
dysfunction) of these responses. Furthermore, it is
important to take multiple baseline samples to
correct for ‘normal’ fluctuations and to use pre-
and well-defined response measures.78,105 Assays to
follow the evoked immune response include
traditional ELISpots both directly ex vivo and after
short (i.e. 1–3 weeks) culture with vaccine
constituents and/or overlapping peptide pools of
preferably the separate HBV antigens, T-cell
proliferation assays and finally extensive immune
phenotyping and/or single cell RNA sequencing of
T cells cognate for (pools of) epitopes using
advanced HLA-multimer technologies.33,34,40,78
Wherever possible not only the peripheral, but also
the hepatic compartment should be sampled.
Rational attempts should be made to correlate the
size, quality and characteristics of the immune
responses to effects of the vaccine on viral control.
For the latter, besides traditional parameters (i.e.
HBsAg, HBeAg and HBV DNA) several alternative
markers have recently surfaced. These are
important because HBsAg from integrated DNA
may shield any effect on HBsAg from productively
infected cells, while NA therapy (inhibiting Pol to
synthesise relaxed circular (rc)DNA from
pregenomic (pg)RNA) may mask effects on viral
DNA.3,4 One of the novel markers is serum pgRNA,
which in NA treated patients may better represent
cccDNA transcriptional activity than serum
DNA.4,108–110 A second novel marker is HBV core
related antigen (HBcrAg), which represents a
combination of proteins produced from the Core/
Precore ORF and was found to correlate better
with cccDNA transcriptional activity than HBsAg,
HBV DNA or pgRNA.111,112 Positive effects of TV on
2021 | Vol. 10 | e1232
Page 12
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
Therapeutic vaccines for chronic hepatitis B DTSL Jansen et al.
HBcrAg and pgRNA could thus represent an
important sign of emerging viral immune control.
Moreover, these markers could indicate whether
TV can precondition patients for other forms of
therapy or NA discontinuation. Lastly, although in
need of validation, serum cccDNA could be of
interest as it may reflect killing of cccDNA
containing hepatocytes.113
Other opportunities for combination
(immune) therapy
T-cell responses to HBV antigens boosted/induced
by TV may be further improved by ICB, co-
stimulatory agonists and drugs altering T-cell
metabolism.10,24,32,114,115 As outlined above,
recent studies strongly indicate that for each viral
protein the mechanisms and deficits of T-cell
priming are different and likewise that different
strategies may be required to activate, boost or
rescue cognate T cells specific for each of these
proteins. For example one could argue that for
(part of the) HBcAg-specific CD8+ T-cell responses,
ICB alone may already be effective in some
patients, while for Pol-specific CD8+ T cells support
of T-cell priming could first be needed.33,34,116,117
Such support could be delivered either by TV or
by an in situ vaccine effect of hepatocytes killed
by T cells of a different specificity (e.g. HBcAg) as
was seen in the GS-4774 trial.65
Although still requiring a randomised large-
scale follow-up, a recent study combining yeast-
based GS-4774 together with ICB (anti-PD1)
showed HBsAg decline in several patients and one
patient achieving functional cure. In this small
(suboptimal, mostly Asian and Polynesian) cohort
the induced HBsAg decline was not further
facilitated by GS-4774 pretreatment.117
Nonetheless, combination of (future generations
of) TV with other ways of lifting immune
suppression are worth exploring as is also
highlighted by recent studies in HPV-induced
malignant disease and melanoma, where clinical
responses to SLP/RNA vaccination were facilitated
by depletion of myeloid derived suppressor cells
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Figure 1. Considerations for the next generation of TV. Before TV administration, viral load may need to be reduced by NA and/or siRNA
treatment. When viral load (and ALT) are stably low, TV can be given preferably intradermal (ID) or intranodal (IN). To further improve T-cell
effector function, TV can be combined with suppressive myeloid cell (MDSC) targeting drugs (given before TV), T-cell metabolism modifying
drugs (before or during TV) or checkpoint blockade (during or after TV). As a ‘natural’ booster, NAs can be stopped to increase viral antigen
presentation boosting HBV-specific T cells in situ to drive clearance of remaining infected hepatocytes. Adequate monitoring of the viral as well as
immunological response is pivotal to evaluate vaccine efficacy. Multiple baseline samples are desired. In addition to traditional viral markers also,
novel markers may be monitored. Immune monitoring should be as detailed as possible on peripheral blood samples, but whenever possible also
on hepatic samples. Lines provide a schematic indication of the development of the indicated parameter over time. Coloured arrows match the
boxes below the graphs and schematically indicate preferred moments of intervention or monitoring.
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Also of high interest to combine with TV and/or
drugs to lift immune suppression are therapeutic
modalities specifically aimed at elimination of the
vast load of HBsAg by interfering RNAs.3 In mice
it has been demonstrated that knockdown of HBV
antigens by siRNA in combination with TV (but
not siRNA alone or TV alone) increased HBV-
specific effector T-cell numbers resulting in loss of
serum HBsAg, HBeAg and HBV DNA, development
of high anti-HBs titres and anti-HBeAg
seroconversion indicating a cure of HBV
infection.119 So these data indicate that reducing
HBsAg levels using siRNAs support the effectivity
of the TV. As HBsAg levels do not seem to directly
affect global or HBV-specific T-cell responses the
support of siRNA may be explained by effects of
HBsAg on sustaining HBV replication and/or on B
cell responses, which likely also contribute to viral
clearance.35,120 A clinical study in humans and
chimpanzees with siRNA targeting HBsAg was
unfortunately not successful as it did not affect
HBsAg expression from integrated DNA.3 Clinical
results of follow-up studies with siRNA that also
silences this HBsAg are now eagerly awaited.
CONCLUDING REMARKS
Taken together, based on results from other
diseases we might deduce that SLP and nucleic
acid-based vaccines may have a high potency in
the fight against cHBV. Their full potential,
however, may only be exploited when the right
(parts of) HBV antigens are targeted, when the
latest mechanistic insight into in vivo vaccine
handling by APCs at different anatomical sites
are considered and when adjuvant and route of
administration are rationally matched to the
platform and the desired immunological
outcome. For optimal effect of vaccination, it is
likely essential to take a stepwise approach, first
reducing viral load by NA therapy and/or by
siRNA-based therapeutic modalities (Figure 1).
Combination or follow-up with ICB, metabolism-
altering drugs or those targeting suppressive
myeloid cells may be useful to harness both
existing responses and to further boost TV-
induced responses. Ultimately, patients with
effective T cells and temporarily alleviated HBsAg
levels may benefit from a well-timed, controlled
and monitored NA stop to obtain a natural
‘booster’ for the immune system and allow
immune clearance of the remaining infected
cells.
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